MedPath

Pilot study to evaluate glycemic control using GlucoTab in combination with continuous glucose monitoring in non-critically ill patients with type 2 diabetes at the general ward

Phase 4
Recruiting
Conditions
E11
Type 2 diabetes mellitus
Registration Number
DRKS00030400
Lead Sponsor
Medizinische Universität Graz
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
30
Inclusion Criteria

Informed consent obtained after being advised
of the nature of the study
-Male or female aged =18 years
-Type 2 diabetes (treated with diet, oral agents,
non-insulin injected anti-diabetic medicine,
insulin therapy or any combination of the four)
or newly diagnosed hyperglycemia which
requires s.c. insulin therapy

Exclusion Criteria

- Type 1 diabetes, gestational diabetes
- Any disease or condition which the
investigator or treating physician feels would
interfere with the trial or the safety of the
patient
- Hyperglycaemic episodes (ketoacidosis,
hyperosmolar state) if they require intravenous
insulin therapy
- Pregnancy
- Any mental condition rendering the patient
incapable of giving his consent
- Known or suspected allergy to adhesive
material/tape
- Skin pathologies that hinder application of a
CGM sensor
- Continuous parenteral nutrition
- Participation in another trial which can
influence outcome of the trial

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Mean percentage of blood glucose <br>measurements in the target range 70 to 140 <br>mg/dl, as calculated by all premeal and bedtime<br>blood glucose values measured = 24 hours <br>after start of therapy
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath